Stocks Johnson & Johnson

More

  • Stocks surge in lockstep with oil's rally Friday, 22 Jan 2016 | 6:45 AM ET
    Oil pump on Dollar note

    The promise of more monetary easing around the world and an extension of Thursday's crude rally were factors helping propel global markets this morning.

  • Will the market get Trump'd? Thursday, 21 Jan 2016 | 12:50 PM ET
    Donald Trump

    Trump is a businessman. But if he becomes president, will he be good for the market?

  • Burned investors: Just give up on oil already Wednesday, 20 Jan 2016 | 10:03 AM ET

    For investors who have grown frustrated with trying to time a rebound in oil prices, here's an idea: Forget about oil entirely.

  • Street: S&P 500 prices in 50% chance of a recession Wednesday, 20 Jan 2016 | 6:00 AM ET
    A trader on the floor of the New York Stock Exchange

    Equity strategists at two major investment banks told clients Tuesday that the stock market is pricing in a high risk of a recession.

  • HR Experts Talk What They're Buying During Volatility Tuesday, 19 Jan 2016 | 3:00 PM ET

    During a time of global volatility, the HR experts discuss what names are safe bets

  • J&J to cut 3,000 jobs in medical devices division Tuesday, 19 Jan 2016 | 10:46 AM ET
    Johnson & Johnson

    Johnson & Johnson said it would cut about 3,000 jobs within its medical devices division, or between 4 percent and 6 percent of the unit's workforce.

  • This is the easy way to find stock market bargains Friday, 15 Jan 2016 | 8:00 AM ET
    Johnson & Johnson products

    Two factors may tell you whether a stock is an attractive value pick.

  • Red alert: A $1 trillion stock bubble ready to pop Thursday, 14 Jan 2016 | 9:48 AM ET
    financial bubble NYSE

    Hypergrowth in ETF Index funds is posing a big market risk, experts warn. It's time for investors to look at diversifying their holdings.

  • These are the stocks that do best in rocky markets Monday, 11 Jan 2016 | 9:43 AM ET

    Rising interest rates and wobbly markets may roil some stocks, but experts believe these picks will profitably ride out the storm.

  • Jan 4- Johnson and Johnson is seeking to sell its manufacturer of active pharmaceutical ingredients, Noramco, in a move that could value the division at as much as $800 million, according to people familiar with the matter. The unit has annual earnings before interest, taxes, depreciation and amortization of more than $70 million, some of the people added.

  • Over the past several years, the FDA has received thousands of reports of complications, including bleeding, organ perforation and urinary problems, involving the use of mesh for transvaginal POP repair, the agency said. The FDA noted that an advisory panel of experts in 2011 recommended that more data was needed to establish their safety.

  • A $27,500 strip-club bill and more outrage of 2015 Thursday, 31 Dec 2015 | 12:56 PM ET

    The most expensive strip-club bill, the most hated man in America and more of the best, worst and WTF of 2015.

  • My top 10 stock picks for 2016: Farr Wednesday, 30 Dec 2015 | 10:33 AM ET
    2016

    CVS, Chevron, and J&J are among Michael Farr's top 10 stock picks for 2016. Here's why those and seven others made the list.

  • Dec 23- Kentucky reached two separate settlements totaling $39.5 million with Purdue Pharma and Johnson& Johnson, Attorney General Jack Conway said on Wednesday. Purdue, which settled for $24 million, was alleged to have misrepresented the highly addictive nature of its drug OxyContin. A separate $15.5 million settlement involved Johnson& Johnson's unit,...

  • NEW YORK, Dec 23- A new class of blood thinners that competes with widely used warfarin should get a boost next year when an "antidote" that can reverse the medications' effects in an emergency is expected to enter the market, according to top U.S. heart doctors and investors. Xarelto, from Bayer AG and Johnson& Johnson, and Eliquis, sold by Bristol-Myers Squibb and...

  • LONDON, Dec 17- After being vindicated in her 2014 purchase of a U.S. company with a device to prop open diseased lungs, the chief executive of British healthcare group BTG is scouring the horizon for the next promising acquisition. BTG is best known for treating rattlesnake bites, with its antivenom drug CroFab, but Louise Makin sees a different future for the...

  • WASHINGTON, Dec 17- The number of Americans filing for unemployment benefits last week fell from a five-month high, suggesting sustained labor market healing that could lead to further Federal Reserve interest rate hikes next year. Initial claims for state unemployment benefits dropped 11,000 to a seasonally adjusted 271,000 for the week ended Dec. 12, the...

  • U.S. Q3 current account deficit largest since 2008 Thursday, 17 Dec 2015 | 8:30 AM ET

    WASHINGTON, Dec 17- The U.S. current account deficit in the third quarter widened sharply to its highest level in nearly seven years as a strong dollar weighed on exports and the profits of multinational corporations. The Commerce Department said on Thursday the current account deficit, which measures the flow of goods, services and investments into and out of...

  • *AstraZeneca says acalabrutinib sales could top $5 bln/ yr. LONDON, Dec 17- AstraZeneca said on Thursday it had agreed to buy 55 percent stake of privately held biotech firm Acerta Pharma for $4.0 billion to give it access to a new kind of drug for fighting blood cancers. AstraZeneca will pay $2.5 billion upfront, with a further $1.5 billion paid either on receipt of...

  • WASHINGTON, Dec 15- President Barack Obama, who made few friends in corporate board rooms early in his first term as he pressed for tighter regulations on banks and remarked on the "fat cats" who helped precipitate the financial crisis, heads into his final year in the White House having built- or rebuilt- alliances with chief executives of the nation's biggest...